Aurobindo Pharma’s CuraTeQ achieves Phase 3 success for Omalizumab biosimilar

The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline

AstraZeneca, Roche-backed study supports risk-based HF screening in diabetes

Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care

AstraZeneca combo therapy shows breakthrough in liver cancer trial

The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan

Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment

The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Merck secures landmark EU nod for KEYTRUDA in hard-to-treat ovarian cancer

Its a major breakthrough for women’s ovarian cancer care in Europe

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million

Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy

The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases